Literature DB >> 24965546

A clinical and nutritional comparison of biliopancreatic diversion performed with different common and alimentary channel lengths.

Giuseppe Currò1, Tommaso Centorrino, Andrea Cogliandolo, Arturo Dattola, Grazia Pagano, Alberto Barbera, Giuseppe Navarra.   

Abstract

BACKGROUND: This retrospective study compares the clinical and nutritional outcomes of 100 morbidly obese patients who underwent biliopancreatic diversion (BPD) with common (CC) and alimentary channel (AC) length, respectively, 50/250 and 80/200 cm.
METHODS: One hundred patients who received BPD from October 2006 to November 2011 were identified from a database of bariatric procedures performed at the University Hospital of Messina, and the outcomes in terms of weight loss and morbidity were compared. Forty morbidly obese patients underwent BPD with CC 80 cm and AC 200 cm (group 1) and 60 morbidly obese patients underwent BPD with CC 50 cm and AC 250 cm (group 2).
RESULTS: A gradual weight loss was observed in both groups during the first 3 years after the operation without any significant difference between the two groups. Two cases of protein malnutrition occurred in the group 2 (3 %) due to poor patient compliance in terms of adequate dietary protein intake. Sideropenic anemia was found in 42 % of obese patients in group 2 versus 22.5 % in group 1 at third-year follow-up despite adequate supplementation (p = 0.047). Diarrhea occurred more frequently with a shorter CC. Lipophilic vitamin deficiencies occurred more frequently with a shorter CC despite adequate oral supplementation.
CONCLUSIONS: In the medium term, our series showed that shorter CC was associated with no weight loss advantage but with higher morbidity rate, especially in young and fertile women. We recommend a longer CC (80 cm) to be performed especially in this sub-population of obese patients.

Entities:  

Mesh:

Year:  2015        PMID: 24965546     DOI: 10.1007/s11695-014-1347-2

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  17 in total

1.  Biliopancreatic Diversion with Gastrectomy as Surgical Treatment of Morbid Obesity.

Authors: 
Journal:  Obes Surg       Date:  1991-12       Impact factor: 4.129

2.  Incisional hernia prophylaxis in morbidly obese patients undergoing biliopancreatic diversion.

Authors:  Giuseppe Currò; Tommaso Centorrino; Cinzia Musolino; Giuseppe Sarra; Giuseppe Navarra
Journal:  Obes Surg       Date:  2011-10       Impact factor: 4.129

3.  Commonwealth of Massachusetts Betsy Lehman Center for Patient Safety andMedical Error Reduction Expert Panel on Weight Loss Surgery: executive report.

Authors: 
Journal:  Obes Res       Date:  2005-02

4.  Long-term outcome with the prophylactic use of polypropylene mesh in morbidly obese patients undergoing biliopancreatic diversion.

Authors:  Giuseppe Curro; Tommaso Centorrino; Vanessa Low; Giuseppe Sarra; Giuseppe Navarra
Journal:  Obes Surg       Date:  2012-02       Impact factor: 4.129

Review 5.  The importance of the length of the limbs for gastric bypass patients--an evidence-based review.

Authors:  Dimitrios Stefanidis; Timothy S Kuwada; Keith S Gersin
Journal:  Obes Surg       Date:  2011-01       Impact factor: 4.129

6.  Common channel length predicts outcomes of biliopancreatic diversion alone and with the duodenal switch surgery.

Authors:  Donald B McConnell; Robert W O'rourke; Clifford W Deveney
Journal:  Am J Surg       Date:  2005-05       Impact factor: 2.565

7.  Plasma insulin and glucose time courses after biliary pancreatic diversion in morbidly obese patients with and without diabetes.

Authors:  Giuseppe Currò; Tommaso Centorrino; Vanessa Low; Giuseppe Navarra
Journal:  Am J Surg       Date:  2012-04-04       Impact factor: 2.565

8.  Biliopancreatic diversion.

Authors:  N Scopinaro; G F Adami; G M Marinari; E Gianetta; E Traverso; D Friedman; G Camerini; G Baschieri; A Simonelli
Journal:  World J Surg       Date:  1998-09       Impact factor: 3.352

9.  Evolution of operative procedures for the management of morbid obesity 1950-2000.

Authors:  Henry Buchwald; Jane N Buchwald
Journal:  Obes Surg       Date:  2002-10       Impact factor: 4.129

10.  A clinical and nutritional comparison of biliopancreatic diversion with and without duodenal switch.

Authors:  Kevin Dolan; Michael Hatzifotis; Leyanne Newbury; Nadine Lowe; George Fielding
Journal:  Ann Surg       Date:  2004-07       Impact factor: 12.969

View more
  5 in total

1.  Clinical and Metabolic Effects of Biliopancreatic Diversion Persist After Reduction of the Gastric Pouch and Elongation of the Common Alimentary Tract. Preliminary Report in a Series of Patients with a 10-Year Follow-Up.

Authors:  Valerio Ceriani; Francesco Cetta; Tiziana Lodi; Ferdinando Pinna; Antonio E Pontiroli
Journal:  Obes Surg       Date:  2017-06       Impact factor: 4.129

2.  Common Channel Length in Bypass Surgery Does Not Impact T2DM in Diabetic Zucker Rats.

Authors:  Claudia Laessle; Sven Michelmichel; Goran Marjanovic; Simon Kuesters; Gabriel Seifert; Ulrich T Hopt; Jodok Matthias Fink
Journal:  Obes Surg       Date:  2017-08       Impact factor: 4.129

3.  Vitamin and Mineral Deficiencies After Biliopancreatic Diversion and Biliopancreatic Diversion with Duodenal Switch--the Rule Rather than the Exception.

Authors:  Jens Homan; Bark Betzel; Edo O Aarts; K Dogan; Kees J H M van Laarhoven; Ignace M C Janssen; Frits J Berends
Journal:  Obes Surg       Date:  2015-09       Impact factor: 4.129

4.  Long-Term Outcomes of Biliopancreatic Diversion on Glycemic Control, Insulin Sensitivity and Beta Cell Function.

Authors:  Ana Carolina Junqueira Vasques; José Carlos Pareja; Maria da Saúde de Oliveira; Fernanda Satake Novaes; Marcelo Miranda Oliveira Lima; Élinton A Chaim; Francesca Piccinini; Chiara Dalla Man; Claudio Cobelli; Bruno Geloneze
Journal:  Obes Surg       Date:  2016-11       Impact factor: 4.129

Review 5.  Diarrhea after bariatric procedures: Diagnosis and therapy.

Authors:  Yves M Borbély; Alice Osterwalder; Dino Kröll; Philipp C Nett; Roman A Inglin
Journal:  World J Gastroenterol       Date:  2017-07-14       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.